ADHD :: Shire announces filing of VYVANSE for treatment of ADHD in adults

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for VYVANSE? (lisdexamfetamine dimesylate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults.

HIV :: A brief skill-building program can reduce STD or HIV risk among women

A brief skill-building program on practices to reduce exposure to sexually transmitted disease (STD) and HIV improved the self-reported protective behaviors of inner-city black women for up to one year and actually decreased their risk of acquiring an STD, according to a study appearing in the June 2007 issue of the American Journal of Public Health.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack